Gen Digital Inc. (GEN) Stock News

A class action lawsuit has been filed against FuelCell Energy, Inc. for allegedly making false and misleading statements regarding its manufacturing capacity, production rates under a capital equipment purchase agreement with Fit Energy, and resulting higher costs. Investors who purchased FCEL securities between June 24, 2026 and September 1, 2026 have until November 10, 2026 to apply as lead plaintiff.

SPIE, the independent European leader in multi-technical services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, an Austrian electrical engineering and automation solutions provider with ~230 employees and €100 million in annual revenue. SAR's Managing Director Arno Reisinger will retain a 24% stake. The acquisition, expected to close in early 2027, strengthens SPIE's presence in Austria and Germany while expanding its portfolio in infrastructure and industrial automation systems.

SPIE, the independent European leader in multi-technical services, has signed an agreement to acquire SAR ANLAGENBAU GmbH, a major provider of electrical engineering and automation solutions in Austria and Germany. SPIE will hold 76% of SAR's capital while SAR's CEO Arno Reisinger will co-invest with up to 24% stake. SAR generated approximately €100 million in revenue in 2025 with 230 employees and strengthens SPIE's capabilities in industrial infrastructure and automation projects. The transaction is expected to close in early 2027.

Qiagen is expected to report Q3 2026 earnings on November 4 with a consensus EPS estimate of $0.63 (down 1.6% YoY) and revenues of $539.44 million (up 1.3% YoY). With a positive Earnings ESP of +4.00% and Zacks Rank #2 (Buy), the company appears positioned to beat consensus estimates. The stock has beaten EPS estimates in 3 of the last 4 quarters.

Bragar Eagel & Squire, P.C. has filed class action lawsuits against XTI Aerospace, Innventure, and Flotek Industries for allegedly making materially false statements and failing to disclose undisclosed executive activities and disclosure control issues during their respective class periods. Investors have until October 27, 2026 to apply as lead plaintiffs.

Sika reported strong nine-month results with 4.8% sales growth in local currencies, reaching CHF 8.71 billion. The company improved its material margin to 55.4% and maintained EBITDA margin at 19.2%. Sika's Fast Forward cost-saving program is on track to deliver CHF 80 million in savings by 2026. The company completed acquisitions of Akkim and Azpects Group, and agreed to acquire Resonac Corporation's adhesives business. Sika confirmed its full-year 2026 guidance of 3-6% sales growth in local currencies.

Halper Sadeh LLC, an investor rights law firm, is investigating QIAGEN N.V., Victory Capital Holdings, Inc., and Rallybio Corporation for potential violations of federal securities laws and breaches of fiduciary duties relating to their proposed mergers and acquisitions. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders.

A class action lawsuit has been filed against AEVEX Corp. alleging that the company and underwriters concealed a pre-arranged plan to prematurely override a 180-day lock-up agreement following its April 2026 IPO. The alleged scheme would have allowed Madison (the majority shareholder) to conduct a secondary public offering worth over $200 million shortly after the IPO. Investors who purchased shares during the IPO or between April 17 and June 4, 2026 have until October 20, 2026 to apply as lead plaintiff.

Bragar Eagel & Squire, P.C. has filed class action lawsuits against Taboola.com Ltd. and GoDaddy Inc. on behalf of investors who suffered losses during specified periods. Taboola.com is accused of making materially false statements regarding low-quality publishers and overstated publisher relationship values. Investors have until October 20, 2026 to apply to be appointed as lead plaintiff in these cases.

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

A class action lawsuit has been filed against The Simply Good Foods Company for allegedly making false statements regarding its OWYN acquisition. The lawsuit claims the company lost key personnel post-acquisition, faced product quality issues with a new pea protein supplier, engaged in excessive discounting to boost sales, and ultimately failed to achieve strategic goals, resulting in significant operational and financial problems for the OWYN segment.

A class action lawsuit has been filed against Datavault AI Inc. (NASDAQ: DVLT) for allegedly making materially false and misleading statements regarding corporate partnerships, trading volume on its platform, and undisclosed connections to a convicted felon. Investors who purchased securities between September 4, 2024 and October 30, 2025 have until October 5, 2026 to apply for lead plaintiff status.

Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.

GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been included in the Euronext Paris indices CAC Mid 60 and SBF 120, effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its reputation among institutional investors. The company continues to develop therapeutic and diagnostic solutions, including the FDA-approved Iqirvo® for primary biliary cholangitis.

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been admitted to the Euronext Paris CAC Mid 60 and SBF 120 indices effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its profile among institutional investors.

Hagens Berman has filed a securities fraud class action lawsuit against HDFC Bank Limited and its executives, alleging the bank concealed a scheme involving approximately Rs 45 crore ($4.7 million USD) in disguised payments to induce state deposits while providing above-market interest rates. The fraudulent practices allegedly violated RBI regulations and the bank's internal policies, resulting in overstated financials. The scheme surfaced following the resignation of the Chairman in March 2026 and an investigative report in May 2026, causing HDFC's stock to decline sharply. The class period covers July 17, 2023 to May 26, 2026, with a lead plaintiff deadline of October 13, 2026.

A comparison of Gen Digital (GEN) and Zeta Global Holdings (ZETA) as value investment opportunities. Gen Digital emerges as the superior value option with a Zacks Rank of #2 (Buy) versus ZETA's #3 (Hold), a lower forward P/E ratio of 10.65 compared to ZETA's 31.67, and a stronger Value grade of B versus ZETA's D grade.

Law firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.

Amgen Inc. disclosed a material data breach in July 2026 involving unauthorized access to cloud environments hosted by third-party providers, resulting in the exfiltration of patient protected health information and proprietary company data. The national class action law firm Edelson Lechtzin LLP is investigating potential legal claims on behalf of affected individuals and offering free case evaluations.

A securities class action has been filed against Cogent Communications Holdings, Inc. (CCOI) alleging the company made misleading statements about its dividend sustainability and pledged share risks. CCOI stock declined over 80% and the dividend was cut by 98%, with lenders seizing and selling $82.5 million in pledged stock. Investors who purchased between February 29, 2024 and May 1, 2026 may be eligible to participate in the lawsuit, with a September 21, 2026 deadline for lead plaintiff applications.

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false statements about Fabric Genomics and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx revealed a $57.5 million operational loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price fell approximately 50% from $67.93 to $34.51 per share. Investors have until August 3, 2026 to apply as lead plaintiff.

Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.

GENFIT announced positive Phase 1b results for GNS561, an investigational drug targeting autophagy, in combination with a MEK inhibitor for treating advanced KRAS-mutated cholangiocarcinoma. The study of 19 patients showed a favorable safety profile with no dose-limiting toxicities and early signs of antitumor activity, with approximately half achieving stable disease. Phase 2 initiation is planned for the second half of 2026.

GENFIT reported positive Phase 1b results for GNS561 combined with a MEK inhibitor in heavily pretreated cholangiocarcinoma patients with KRAS mutations. The drug demonstrated favorable safety and tolerability profiles with no dose-limiting toxicities, along with early signs of antitumor activity. Approximately half of the 19 patients achieved stable disease at Week 6, with one patient maintaining this status through Week 30. The company plans to extend Phase 1b with additional cohorts at higher doses and proceed to Phase 2 launch in H2 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited (RGC) and AeroVironment, Inc. (AVAV) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure during their respective class periods.

Excluding significant items, quarterly earnings per common share of $0.48 (1) Increased quarterly dividend 17.6 % to $ 0.10 per common share TORONTO , June 3, 2026 /CNW/ - Canaccord Genuity Group Inc. (Canaccord Genuity Group, the Company) (TSX: CF ) today announced its financial results for the fourth quarter and fiscal year ended March 31, 2026. "We delivered record revenue in fiscal 2026 and significantly improved profitability, reflecting stronger operating leverage and disciplined execution across the platform," said Dan Daviau, Chairman & CEO of Canaccord Genuity Group Inc. "Capital markets growth was led by higher investment banking and advisory activity, while wealth management continued to scale, supported by market appreciation, targeted investment and positive inflows. Our improved earnings profile and continued focus on disciplined capital allocation supported our decision to increase the dividend, while preserving the flexibility to invest in the areas of the business where we see the strongest opportunities to create long-term shareholder value." Fourth quarter and fiscal 2026 highlights (adjusted): (All dollar amounts are stated in thousands of Canadian dollars and on an adjusted basis excluding significant items ( 1 ) unless otherwise indicated) Fourth quarter revenue of $612.7 million, an increase of 33.2% over the same period in the prior fiscal year and the third highest quarterly revenue on record Fiscal 2026 revenue of $2.2 billion increased by 24.9% year over year Global wealth management operations earned record quarterly revenue of $306.7 million and record revenue of $1.1 billion for fiscal 2026, year-over-year improvements of 28.4% and 24.2%. Fourth quarter growth in the Australian wealth management operations reflects contributions from the acquisition of Wilsons Advisory Global capital markets revenue for the fourth quarter of $291.6 mi

Publicis Groupe held its annual shareholders' meeting on May 27, 2026, with an 80.78% quorum approving all 23 resolutions. The company approved a dividend increase of 4.17% to 3.75 euros per share and appointed new board members Benjamin Badinter and Jaime Teevan. CEO Arthur Sadoun highlighted strong 2025 performance with 5.6% organic growth and confirmed 2026 objectives despite uncertain macroeconomic conditions.

Metallium Limited presented its patented Flash Joule Heating (FJH) technology at the Canaccord Genuity Global Metals and Mining Conference, positioning it as a solution to reduce U.S. reliance on China for critical metals processing. The company, which recently received a Department of War grant for gallium and germanium recovery from e-waste, is pursuing a NASDAQ uplist expected later in 2026 and focusing on urban mining/recycling and mineral processing verticals.